Optimal Use of Sandimmun in Nephrotic Syndrome:
Since 1978, when Sandimmun was first used in humans, great experience has been gathered in clinical transplantation by the treatment of about half a million patients. The experience with Sandimmun in nephrotic syndrome is put into perspective and compared with alternatives such as corticosteroids an...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Berlin, Heidelberg
Springer Berlin Heidelberg
1992
|
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | Since 1978, when Sandimmun was first used in humans, great experience has been gathered in clinical transplantation by the treatment of about half a million patients. The experience with Sandimmun in nephrotic syndrome is put into perspective and compared with alternatives such as corticosteroids and cytotoxic agents. Sandimmun may be regarded as a leap forward in the treatment of that population of patients that do not satisfactorily respond to steroids. The possibility of drastically reducing the use of corticosteroids, particularly in children, is perhaps the most attractive feature of Sandimmun. This book gives the results ofa worldwide clinical programme. It includes authors' personal experience as well as an analysis of all data made available. A careful assessment of reported side effects is also given |
| Beschreibung: | 1 Online-Ressource (VI, 34 p. 10 illus) |
| ISBN: | 9783642773105 |
| DOI: | 10.1007/978-3-642-77310-5 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046145634 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s1992 |||| o||u| ||||||eng d | ||
| 020 | |a 9783642773105 |9 978-3-642-77310-5 | ||
| 024 | 7 | |a 10.1007/978-3-642-77310-5 |2 doi | |
| 035 | |a (ZDB-2-SME)978-3-642-77310-5 | ||
| 035 | |a (OCoLC)1119009944 | ||
| 035 | |a (DE-599)BVBBV046145634 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.61 |2 23 | |
| 100 | 1 | |a Meyrier, A. |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Optimal Use of Sandimmun in Nephrotic Syndrome |c by A. Meyrier, P. Niaudet, J. Brodehl |
| 264 | 1 | |a Berlin, Heidelberg |b Springer Berlin Heidelberg |c 1992 | |
| 300 | |a 1 Online-Ressource (VI, 34 p. 10 illus) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 520 | |a Since 1978, when Sandimmun was first used in humans, great experience has been gathered in clinical transplantation by the treatment of about half a million patients. The experience with Sandimmun in nephrotic syndrome is put into perspective and compared with alternatives such as corticosteroids and cytotoxic agents. Sandimmun may be regarded as a leap forward in the treatment of that population of patients that do not satisfactorily respond to steroids. The possibility of drastically reducing the use of corticosteroids, particularly in children, is perhaps the most attractive feature of Sandimmun. This book gives the results ofa worldwide clinical programme. It includes authors' personal experience as well as an analysis of all data made available. A careful assessment of reported side effects is also given | ||
| 650 | 4 | |a Nephrology | |
| 650 | 4 | |a Pharmacology/Toxicology | |
| 650 | 4 | |a Allergology | |
| 650 | 4 | |a Immunology | |
| 650 | 4 | |a Nephrology | |
| 650 | 4 | |a Toxicology | |
| 650 | 4 | |a Allergy | |
| 650 | 4 | |a Immunology | |
| 700 | 1 | |a Niaudet, P. |4 aut | |
| 700 | 1 | |a Brodehl, J. |4 aut | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783540551805 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783642773112 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-642-77310-5 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031525819 | ||
| 966 | e | |u https://doi.org/10.1007/978-3-642-77310-5 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180482564292608 |
|---|---|
| any_adam_object | |
| author | Meyrier, A. Niaudet, P. Brodehl, J. |
| author_facet | Meyrier, A. Niaudet, P. Brodehl, J. |
| author_role | aut aut aut |
| author_sort | Meyrier, A. |
| author_variant | a m am p n pn j b jb |
| building | Verbundindex |
| bvnumber | BV046145634 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-3-642-77310-5 (OCoLC)1119009944 (DE-599)BVBBV046145634 |
| dewey-full | 616.61 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.61 |
| dewey-search | 616.61 |
| dewey-sort | 3616.61 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-3-642-77310-5 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02455nmm a2200493zc 4500</leader><controlfield tag="001">BV046145634</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s1992 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783642773105</subfield><subfield code="9">978-3-642-77310-5</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-3-642-77310-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-3-642-77310-5</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119009944</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046145634</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.61</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Meyrier, A.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Optimal Use of Sandimmun in Nephrotic Syndrome</subfield><subfield code="c">by A. Meyrier, P. Niaudet, J. Brodehl</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin, Heidelberg</subfield><subfield code="b">Springer Berlin Heidelberg</subfield><subfield code="c">1992</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (VI, 34 p. 10 illus)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Since 1978, when Sandimmun was first used in humans, great experience has been gathered in clinical transplantation by the treatment of about half a million patients. The experience with Sandimmun in nephrotic syndrome is put into perspective and compared with alternatives such as corticosteroids and cytotoxic agents. Sandimmun may be regarded as a leap forward in the treatment of that population of patients that do not satisfactorily respond to steroids. The possibility of drastically reducing the use of corticosteroids, particularly in children, is perhaps the most attractive feature of Sandimmun. This book gives the results ofa worldwide clinical programme. It includes authors' personal experience as well as an analysis of all data made available. A careful assessment of reported side effects is also given</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nephrology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacology/Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Allergology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nephrology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Allergy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunology</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Niaudet, P.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brodehl, J.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783540551805</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783642773112</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-3-642-77310-5</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031525819</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-3-642-77310-5</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV046145634 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:28Z |
| institution | BVB |
| isbn | 9783642773105 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031525819 |
| oclc_num | 1119009944 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (VI, 34 p. 10 illus) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 1992 |
| publishDateSearch | 1992 |
| publishDateSort | 1992 |
| publisher | Springer Berlin Heidelberg |
| record_format | marc |
| spelling | Meyrier, A. Verfasser aut Optimal Use of Sandimmun in Nephrotic Syndrome by A. Meyrier, P. Niaudet, J. Brodehl Berlin, Heidelberg Springer Berlin Heidelberg 1992 1 Online-Ressource (VI, 34 p. 10 illus) txt rdacontent c rdamedia cr rdacarrier Since 1978, when Sandimmun was first used in humans, great experience has been gathered in clinical transplantation by the treatment of about half a million patients. The experience with Sandimmun in nephrotic syndrome is put into perspective and compared with alternatives such as corticosteroids and cytotoxic agents. Sandimmun may be regarded as a leap forward in the treatment of that population of patients that do not satisfactorily respond to steroids. The possibility of drastically reducing the use of corticosteroids, particularly in children, is perhaps the most attractive feature of Sandimmun. This book gives the results ofa worldwide clinical programme. It includes authors' personal experience as well as an analysis of all data made available. A careful assessment of reported side effects is also given Nephrology Pharmacology/Toxicology Allergology Immunology Toxicology Allergy Niaudet, P. aut Brodehl, J. aut Erscheint auch als Druck-Ausgabe 9783540551805 Erscheint auch als Druck-Ausgabe 9783642773112 https://doi.org/10.1007/978-3-642-77310-5 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Meyrier, A. Niaudet, P. Brodehl, J. Optimal Use of Sandimmun in Nephrotic Syndrome Nephrology Pharmacology/Toxicology Allergology Immunology Toxicology Allergy |
| title | Optimal Use of Sandimmun in Nephrotic Syndrome |
| title_auth | Optimal Use of Sandimmun in Nephrotic Syndrome |
| title_exact_search | Optimal Use of Sandimmun in Nephrotic Syndrome |
| title_full | Optimal Use of Sandimmun in Nephrotic Syndrome by A. Meyrier, P. Niaudet, J. Brodehl |
| title_fullStr | Optimal Use of Sandimmun in Nephrotic Syndrome by A. Meyrier, P. Niaudet, J. Brodehl |
| title_full_unstemmed | Optimal Use of Sandimmun in Nephrotic Syndrome by A. Meyrier, P. Niaudet, J. Brodehl |
| title_short | Optimal Use of Sandimmun in Nephrotic Syndrome |
| title_sort | optimal use of sandimmun in nephrotic syndrome |
| topic | Nephrology Pharmacology/Toxicology Allergology Immunology Toxicology Allergy |
| topic_facet | Nephrology Pharmacology/Toxicology Allergology Immunology Toxicology Allergy |
| url | https://doi.org/10.1007/978-3-642-77310-5 |
| work_keys_str_mv | AT meyriera optimaluseofsandimmuninnephroticsyndrome AT niaudetp optimaluseofsandimmuninnephroticsyndrome AT brodehlj optimaluseofsandimmuninnephroticsyndrome |